CTOs on the Move

SalioGen Therapeutics

www.saliogen.com

 
SalioGen Therapeutics is advancing the Exact DNA Integration Technology (EDIT) platform, the only genome engineering technology that is mammal-derived, for use in potentially curative non-viral gene therapy.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

SalioGen Therapeutics raised $20M on 02/18/2021

Similar Companies

HealthSource Solutions

HealthSource Solutions is a Hopkins, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SeraCare Life Sciences

SeraCare Life Sciences, Inc. is a Milford, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Onconome

Onconome is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

X-Vax Technology

We`re a biotech company committed to developing vaccines against pathogens acquired by mucosal infection such as herpes. Our research leads us to believe that the new approach we`re taking could succeed in defeating herpes by inducing antibodies that mediate the killing of infected cells. We`re strongly committed to this fight, and so far our work has been supported with unprecedented data in multiple preclinical models.

Lysogene

Lysogene is a biopharmaceutical gene therapy company with lead programs in neurodegenerative lysosomal storage disorders that affect children. Founded in 2009 by Karen Aiach, whose own child was affected by a neurodegenerative disease, Lysogene is rooted in a deep and compassionate understanding of the impact these diseases have on patients and families. Karen`s personal experience fuels her determination to deliver real solutions that will improve patient outcomes and enhance quality of life for both patients and caregivers. Over the past 10 years, Lysogene has acquired deep experience in developing gene therapies—from early discovery through the clinical, registration and review phases. Our strong science and execution track record has been validated by our partnership with Sarepta Therapeutics and the support of top-tier investors, with nearly $100m raised since inception.